This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Navidea Biopharmaceuticals Participates In Symposium Focused On Sentinel Lymph Node Biopsy At The International Symposium On Metastasis In Head And Neck Cancer

“In the current standard of care with head and neck tumors, it is not uncommon to remove as many as 60 regional lymph nodes during bilateral neck dissection because of the likelihood that patients may have hidden cancer in the lymph nodes. Sentinel node biopsy allows for a much less invasive and more precise evaluation with reduced surgical side effects” said Dr. Civantos. “Our initial clinical experience with Lymphoseek suggested a high level of accuracy in the identification and mapping of SLNs that may significantly improve the precision and practicality of the procedure. We believe that Lymphoseek may also have special utility to improve localization in certain tumor types such as those found on the floor of the mouth. I fully expect the final results of the multi-institutional trial, when completed, will confirm these impressions.”

“The study of head and neck cancer is part of Navidea’s worldwide strategy to expand the utilization of Lymphoseek into multiple cancer types beyond breast cancer and melanoma and to assist physicians and patients in improving the accuracy of cancer diagnosis and staging,” said Dr. Reininger. “We believe that there are many unmet needs in the lymphatic mapping of other solid tumor cancers where the procedure may be highly useful, but for which a suitable agent has not yet been developed. Lymphoseek targets key predictive lymph nodes through its specifically-designed, receptor-based mechanism and can fill that need and enhance diagnostic accuracy.”

The satellite symposium, Sentinel Lymph Node (SLN) Biopsy in Head and Neck Cancer, was jointly sponsored with SurgicEye GmbH, Munich, Germany.

About Lymphoseek ®

Lymphoseek ® (technetium Tc 99m tilmanocept) Injection is a novel, receptor-targeted, small-molecule, investigational radiopharmaceutical used in lymphatic mapping procedures that are performed to help stage cancers such as breast cancer and melanoma. Lymphoseek is designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer.

Lymphatic mapping is a procedure in which lymph nodes that may contain tumor metastases are identified and biopsied to determine if cancer has spread beyond the primary tumor. Accurate staging of cancer is critical, as it guides therapy decisions and determines patient prognosis and risk of recurrence. According to the American Cancer Society, approximately 229,000 new cases of breast cancer, 76,000 new cases of melanoma and 67,000 new cases of head and neck cancers are expected to be diagnosed in the United States in 2012.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs